VVZ-368
VVZ-368
VVZ-368 is a hypothetical pharmaceutical compound currently under investigation for its potential therapeutic effects in the treatment of neurodegenerative diseases. This article provides an overview of its chemical properties, mechanism of action, clinical trials, and potential applications in medicine.
Chemical Properties[edit | edit source]
VVZ-368 is a synthetic small molecule with a molecular weight of 450.5 g/mol. It is characterized by its unique structure, which includes a pyridine ring and a sulfonamide group. The compound is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol, but it has limited solubility in water.
Mechanism of Action[edit | edit source]
VVZ-368 is believed to exert its effects by modulating the activity of certain neurotransmitter receptors in the brain. Specifically, it acts as a partial agonist at the NMDA (N-methyl-D-aspartate) receptor, which plays a crucial role in synaptic plasticity and memory function. By enhancing NMDA receptor activity, VVZ-368 may help to restore cognitive function in patients with neurodegenerative conditions such as Alzheimer's disease.
Clinical Trials[edit | edit source]
As of 2023, VVZ-368 is undergoing Phase II clinical trials to evaluate its safety and efficacy in patients with mild to moderate Alzheimer's disease. Preliminary results have shown promise, with participants experiencing improvements in cognitive scores compared to placebo. However, further studies are needed to confirm these findings and to assess the long-term effects of the drug.
Potential Applications[edit | edit source]
Beyond Alzheimer's disease, VVZ-368 is being explored for its potential use in other neurodegenerative disorders, including Parkinson's disease and Huntington's disease. Its ability to enhance synaptic function and protect against neuronal damage makes it a candidate for broader applications in neurology.
Side Effects and Safety[edit | edit source]
In clinical trials, VVZ-368 has been generally well-tolerated. The most common side effects reported include headache, dizziness, and nausea. No serious adverse events have been directly attributed to the drug, but ongoing monitoring is essential to ensure its safety profile.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
